The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Ustekinumab Induction and Maintenance Therapy in Refractory Crohn's Disease
Abstract
BACKGROUND: In patients with Crohn's disease, the efficacy of ustekinumab, a human monoclonal antibody against interleukin-12 and interleukin-23, is unknown. METHODS: We evaluated ustekinumab in adults with moderate-to-severe Crohn's disease that was resistant to anti-tumor necrosis factor (TNF) treatment. During induction, 526 patients were randomly assigned to receive intravenous ustekinumab (at a dose of 1, 3, or 6 mg per kilogram of body weight) or placebo at week 0. During the maintenance phase, 145 patients who had a response to ustekinumab at 6 weeks underwent a second randomization to receive subcutaneous injections of ustekinumab (90 mg) or placebo at weeks 8 and 16. The primary end point was a clinical response at 6 weeks. RESULTS: The proportions of patients who reached the primary end point were 36.6%, 34.1%, and 39.7% for 1, 3, and 6 mg of ustekinumab per kilogram, respectively, as compared with 23.5% for placebo (P=0.005 for the comparison with the 6-mg group). The rate of clinical remission with the 6-mg dose did not differ significantly from the rate with placebo at 6 weeks. Maintenance therapy with ustekinumab, as compared with placebo, resulted in significantly increased rates of clinical remission (41.7% vs. 27.4%, P=0.03) and response (69.4% vs. 42.5%, P<0.001) at 22 weeks. Serious infections occurred in 7 patients (6 receiving ustekinumab) during induction and 11 patients (4 receiving ustekinumab) during maintenance. Basal-cell carcinoma developed in 1 patient receiving ustekinumab. CONCLUSIONS: Patients with moderate-to-severe Crohn's disease that was resistant to TNF antagonists had an increased rate of response to induction with ustekinumab, as compared with placebo. Patients with an initial response to ustekinumab had significantly increased rates of response and remission with ustekinumab as maintenance therapy. (Funded by Janssen Research and Development; CERTIFI ClinicalTrials.gov number, NCT00771667.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial
Hanauer, S. B., Feagan, B. G., Lichtenstein, G. R., Mayer, L. F., Schreiber, S., Colombel, J. F., Rachmilewitz, D., Wolf, D. C., Olson, A., Bao, W., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08512-4 · Cited by 4,169
Self-citationDevelopment of a Crohn's Disease Activity Index
Best, W. R., Becktel, J. M., Singleton, J. W., & Kern, F. (1976) · Gastroenterology · doi:10.1016/s0016-5085(76)80163-1 · Cited by 3,152
Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study.
Best, W. R., Becktel, J. M., Singleton, J. W., & Kern, F. (1976) · PubMed · Cited by 3,147
A Genome-Wide Association Study Identifies IL23R as an Inflammatory Bowel Disease Gene
Duerr, R. H., Taylor, K. D., Brant, S. R., Rioux, J. D., Silverberg, M. S., Daly, M. J., Steinhart, A. H., Abraham, C., Regueiro, M., Griffiths, A., et al. (2006) · Science · doi:10.1126/science.1135245 · Cited by 3,039
Self-citationColombel, J., Sandborn, W. J., Rutgeerts, P., Enns, R., Hanauer, S. B., Panaccione, R., Schreiber, S., Byczkowski, D., Li, J., Kent, J. D., et al. (2007) · Gastroenterology · doi:10.1053/j.gastro.2006.11.041 · Cited by 2,245
Self-citationHanauer, S. B., Sandborn, W. J., Rutgeerts, P., Fedorak, R. N., Lukas, M., MacIntosh, D., Panaccione, R., Wolf, D., & Pollack, P. (2006) · Gastroenterology · doi:10.1053/j.gastro.2005.11.030 · Cited by 1,715
Self-citationIL-23 is essential for T cell–mediated colitis and promotes inflammation via IL-17 and IL-6
Yen, D., Cheung, J., Scheerens, H., Poulet, F., McClanahan, T., Mckenzie, B., Kleinschek, M. A., Owyang, A., Mattson, J., Blumenschein, W., et al. (2006) · Journal of Clinical Investigation · doi:10.1172/jci21404 · Cited by 1,542
Antibodies to interleukin 12 abrogate established experimental colitis in mice.
Neurath, M. F., Fuss, I., Kelsall, B. L., Stüber, E., & Strober, W. (1995) · The Journal of experimental medicine · doi:10.1084/jem.182.5.1281 · Cited by 1,335
Certolizumab Pegol for the Treatment of Crohn's Disease
Sandborn, W. J., Feagan, B. G., Stoinov, S., Honiball, P. J., Rutgeerts, P., Mason, D., Bloomfield, R., & Schreiber, S. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067594 · Cited by 1,143
Self-citationThe IL-23/IL-17 axis in inflammation
Iwakura, Y. (2006) · Journal of Clinical Investigation · doi:10.1172/jci28508 · Cited by 1,046
Cited by
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
Sandborn, W. J., Feagan, B. G., Rutgeerts, P., Hanauer, S., Colombel, J.-F., Sands, B. E., Lukas, M., Fedorak, R. N., Lee, S., Bressler, B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215739 · Cited by 2,719
Self-citationCytokines in inflammatory bowel disease
Neurath, M. F. (2014) · Nature Reviews Immunology · doi:10.1038/nri3661 · Cited by 2,706
Torres, J., Mehandru, S., Colombel, J.-F., & Peyrin-Biroulet, L. (2017) · The Lancet · doi:10.1016/s0140-6736(16)31711-1 · Cited by 2,682
The global burden of IBD: from 2015 to 2025
Kaplan, G. G. (2015) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2015.150 · Cited by 2,639
Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease
Feagan, B. G., Sandborn, W. J., Gasink, C., Jacobstein, D., Lang, Y., Friedman, J. R., Blank, M. A., Johanns, J., Gao, L.-L., Miao, Y., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1602773 · Cited by 1,845
Self-citationThe IL-23-IL-17 immune axis: from mechanisms to therapeutic testing
Gaffen, S. L., Jain, R., Garg, A. V., & Cua, D. J. (2014) · Nature reviews. Immunology · doi:10.1038/nri3707 · Cited by 1,585
de Lange, K. M., Moutsianas, L., Lee, J. C., Lamb, C. A., Luo, Y., Kennedy, N. A., Jostins, L., Rice, D. L., Gutierrez-Achury, J., Ji, S.-G., et al. (2017) · Nature Genetics · doi:10.1038/ng.3760 · Cited by 1,445
ECCO guidelines on therapeutics in Crohn's disease: medical treatment
Torres, J., Bonovas, S., Doherty, G., Kucharzik, T., Gisbert, J. P., Raine, T., Adamina, M., Armuzzi, A., Bachmann, O., Bager, P., et al. (2020) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjz180 · Cited by 1,374
Pathophysiology of Inflammatory Bowel Diseases
Chang, J. T. (2020) · New England Journal of Medicine · doi:10.1056/nejmra2002697 · Cited by 1,295
ECCO Guidelines on Therapeutics in Crohn’s Disease: Surgical Treatment
Adamina, M., Bonovas, S., Raine, T., Spinelli, A., Warusavitarne, J., Armuzzi, A., Bachmann, O., Bager, P., Biancone, L., Bokemeyer, B., et al. (2020) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjz187 · Cited by 1,106
Teng, M. W. L., Bowman, E. P., McElwee, J. J., Smyth, M. J., Casanova, J.-L., Cooper, A. M., & Cua, D. J. (2015) · Nature Medicine · doi:10.1038/nm.3895 · Cited by 873
Martin, J. C., Chang, C., Boschetti, G., Ungaro, R., Giri, M., Grout, J. A., Gettler, K., Chuang, L.-S., Nayar, S., Greenstein, A. J., et al. (2019) · Cell · doi:10.1016/j.cell.2019.08.008 · Cited by 872
IL-17 Signaling: The Yin and the Yang
Amatya, N., Garg, A. V., & Gaffen, S. L. (2017) · Trends in Immunology · doi:10.1016/j.it.2017.01.006 · Cited by 785
Interleukin-23-Independent IL-17 Production Regulates Intestinal Epithelial Permeability
Lee, J. S., Tato, C. M., Joyce-Shaikh, B., Gulen, M. F., Cayatte, C., Chen, Y., Blumenschein, W. M., Judo, M., Ayanoglu, G., McClanahan, T. K., et al. (2015) · Immunity · doi:10.1016/j.immuni.2015.09.003 · Cited by 760
The Medical Management of Paediatric Crohn’s Disease: an ECCO-ESPGHAN Guideline Update
van Rheenen, P. F., Aloi, M., Assa, A., Bronsky, J., Escher, J. C., Fagerberg, U. L., Gasparetto, M., Gerasimidis, K., Griffiths, A., Henderson, P., et al. (2021) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjaa161 · Cited by 729
Targeting immune cell circuits and trafficking in inflammatory bowel disease
Neurath, M. F. (2019) · Nature Immunology · doi:10.1038/s41590-019-0415-0 · Cited by 701
Evidence-based clinical practice guidelines for inflammatory bowel disease
Matsuoka, K., Kobayashi, T., Ueno, F., Matsui, T., Hirai, F., Inoue, N., Kato, J., Kobayashi, K., Kobayashi, K., Koganei, K., et al. (2018) · Journal of Gastroenterology · doi:10.1007/s00535-018-1439-1 · Cited by 698
Current and emerging therapeutic targets for IBD
Neurath, M. F. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2016.208 · Cited by 691
Immunological pathogenesis of inflammatory bowel disease
Lee, S. H., Kwon, J. E., & Cho, M.-L. (2018) · Intestinal Research · doi:10.5217/ir.2018.16.1.26 · Cited by 575
Reich, K., Papp, K. A., Blauvelt, A., Tyring, S. K., Sinclair, R., Thaçi, D., Nograles, K., Mehta, A., Cichanowitz, N., Li, Q., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31279-5 · Cited by 569
Genetic drug target validation using Mendelian randomisation
Schmidt, A. F., Finan, C., Gordillo-Marañón, M., Asselbergs, F. W., Freitag, D. F., Patel, R. S., Tyl, B., Chopade, S., Faraway, R., Zwierzyna, M., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-16969-0 · Cited by 567
Luissint, A.-C., Parkos, C. A., & Nusrat, A. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.07.008 · Cited by 555
Crohn Disease: Epidemiology, Diagnosis, and Management
Feuerstein, J. D., & Cheifetz, A. S. (2017) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2017.04.010 · Cited by 548
15 years of GWAS discovery: Realizing the promise
Abdellaoui, A., Yengo, L., Verweij, K. J. H., & Visscher, P. M. (2023) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2022.12.011 · Cited by 547
Pediatric Crohn disease patients exhibit specific ileal transcriptome and microbiome signature
Haberman, Y., Tickle, T. L., Dexheimer, P. J., Kim, M.-O., Tang, D., Karns, R., Baldassano, R. N., Noe, J. D., Rosh, J., Markowitz, J., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci75436 · Cited by 519
Evidence-based clinical practice guidelines for inflammatory bowel disease 2020
Nakase, H., Uchino, M., Shinzaki, S., Matsuura, M., Matsuoka, K., Kobayashi, T., Saruta, M., Hirai, F., Hata, K., Hiraoka, S., et al. (2021) · Journal of Gastroenterology · doi:10.1007/s00535-021-01784-1 · Cited by 505
Th17 Cell Pathway in Human Immunity: Lessons from Genetics and Therapeutic Interventions
Patel, D. D., & Kuchroo, V. K. (2015) · Immunity · doi:10.1016/j.immuni.2015.12.003 · Cited by 486
Rheumatoid arthritis therapy reappraisal: strategies, opportunities and challenges
Smolen, J. S., & Aletaha, D. (2015) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2015.8 · Cited by 474
IL-12, IL-23 and IL-17 in IBD: immunobiology and therapeutic targeting
Moschen, A. R., Tilg, H., & Raine, T. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-018-0084-8 · Cited by 473
Feagan, B. G., Sandborn, W. J., D'Haens, G., Panés, J., Kaser, A., Ferrante, M., Louis, E., Franchimont, D., Dewit, O., Seidler, U., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30570-6 · Cited by 451
Self-citationPathogenesis of Primary Sclerosing Cholangitis and Advances in Diagnosis and Management
Eaton, J. E., Talwalkar, J. A., Lazaridis, K. N., Gores, G. J., & Lindor, K. D. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.06.052 · Cited by 436
Hui, K. Y., Fernandez-Hernandez, H., Hu, J., Schaffner, A., Pankratz, N., Hsu, N.-Y., Chuang, L.-S., Carmi, S., Villaverde, N., Li, X., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aai7795 · Cited by 384
How Cytokine Networks Fuel Inflammation: Toward a cytokine-based disease taxonomy
Schett, G., Elewaut, D., McInnes, I. B., Dayer, J.-M., & Neurath, M. F. (2013) · Nature Medicine · doi:10.1038/nm.3260 · Cited by 406
ECCO Guidelines on Therapeutics in Crohn’s Disease: Medical Treatment
Gordon, H., Minozzi, S., Kopylov, U., Verstockt, B., Chaparro, M., Buskens, C., Warusavitarne, J., Agrawal, M., Allocca, M., Atreya, R., et al. (2024) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjae091 · Cited by 388
Hazenberg, M. D., & Spits, H. (2014) · Blood · doi:10.1182/blood-2013-11-427781 · Cited by 374
Reframing Immune-Mediated Inflammatory Diseases through Signature Cytokine Hubs
Schett, G., McInnes, I. B., & Neurath, M. F. (2021) · New England Journal of Medicine · doi:10.1056/nejmra1909094 · Cited by 355
Newer Biologic and Small-Molecule Therapies for Inflammatory Bowel Disease
Baumgart, D. C., & Le Berre, C. (2021) · New England Journal of Medicine · doi:10.1056/nejmra1907607 · Cited by 354
Targeting Th17 cells in autoimmune diseases
Yang, J., Sundrud, M. S., Skepner, J., & Yamagata, T. (2014) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2014.07.006 · Cited by 348
Differential Roles for Interleukin-23 and Interleukin-17 in Intestinal Immunoregulation
Maxwell, J. R., Zhang, Y., Brown, W. A., Smith, C. L., Byrne, F. R., Fiorino, M., Stevens, E., Bigler, J., Davis, J. A., Rottman, J. B., et al. (2015) · Immunity · doi:10.1016/j.immuni.2015.08.019 · Cited by 342
Biologic agents for IBD: practical insights
Danese, S., Vuitton, L., & Peyrin-Biroulet, L. (2015) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2015.135 · Cited by 342
Recent advances in inflammatory bowel disease: mucosal immune cells in intestinal inflammation
Cader, M. Z., & Kaser, A. (2013) · Gut · doi:10.1136/gutjnl-2012-303955 · Cited by 337
Beyond Gene Discovery in Inflammatory Bowel Disease: The Emerging Role of Epigenetics
Ventham, N. T., Kennedy, N. A., Nimmo, E. R., & Satsangi, J. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.05.050 · Cited by 320
Role of Th17 Cells in the Pathogenesis of Human IBD
Gálvez, J. (2014) · ISRN Inflammation · doi:10.1155/2014/928461 · Cited by 319
New targets for mucosal healing and therapy in inflammatory bowel diseases
Neurath, M. F. (2014) · Mucosal Immunology · doi:10.1038/mi.2013.73 · Cited by 309
Cytokines as Therapeutic Targets in Rheumatoid Arthritis and Other Inflammatory Diseases
Siebert, S., Tsoukas, A., Robertson, J., & McInnes, I. (2015) · Pharmacological Reviews · doi:10.1124/pr.114.009639 · Cited by 307
Tillack, C., Ehmann, L. M., Friedrich, M., Laubender, R. P., Papay, P., Vogelsang, H., Stallhofer, J., Beigel, F., Bedynek, A., Wetzke, M., et al. (2014) · Gut · doi:10.1136/gutjnl-2012-302853 · Cited by 302
COVID-19 and immunomodulation in IBD
Neurath, M. F. (2020) · Gut · doi:10.1136/gutjnl-2020-321269 · Cited by 302
Nash, P., Kerschbaumer, A., Dörner, T., Dougados, M., Fleischmann, R. M., Geissler, K., McInnes, I., Pope, J. E., van der Heijde, D., Stoffer-Marx, M., et al. (2021) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2020-218398 · Cited by 299
Singh, S., Murad, M. H., Fumery, M., Sedano, R., Jairath, V., Panaccione, R., Sandborn, W. J., & Ma, C. (2021) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(21)00312-5 · Cited by 298
Self-citationGenetics and Pathogenesis of Inflammatory Bowel Disease
Liu, T.-C., & Stappenbeck, T. S. (2016) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-012615-044152 · Cited by 289
Advancing the use of genome-wide association studies for drug repurposing
Reay, W. R., & Cairns, M. J. (2021) · Nature Reviews Genetics · doi:10.1038/s41576-021-00387-z · Cited by 283
Sands, B. E., Chen, J., Feagan, B. G., Penney, M., Rees, W. A., Danese, S., Higgins, P. D. R., Newbold, P., Faggioni, R., Patra, K., et al. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.03.049 · Cited by 279
Self-citationILC3 function as a double-edged sword in inflammatory bowel diseases
Zeng, B., Shi, S., Ashworth, G., Dong, C., Liu, J., & Xing, F. (2019) · Cell Death & Disease · doi:10.1038/s41419-019-1540-2 · Cited by 276
Poddubnyy, D., Hermann, K.-G. A., Callhoff, J., Listing, J., & Sieper, J. (2014) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2013-204248 · Cited by 260
Cho, J. H., & Feldman, M. (2015) · Nature Medicine · doi:10.1038/nm.3897 · Cited by 260
Interleukin-17 in chronic inflammatory neurological diseases
Milovanovic, J., Arsenijevic, A., Stojanovic, B., Kanjevac, T., Arsenijevic, D., Radosavljevic, G., Milovanovic, M., & Arsenijevic, N. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00947 · Cited by 250
A functional genomics predictive network model identifies regulators of inflammatory bowel disease
Peters, L. A., Perrigoue, J., Mortha, A., Iuga, A., Song, W.-M., Neiman, E. M., Llewellyn, S. R., Di Narzo, A., Kidd, B. A., Telesco, S. E., et al. (2017) · Nature Genetics · doi:10.1038/ng.3947 · Cited by 255
Anti-commensal IgG Drives Intestinal Inflammation and Type 17 Immunity in Ulcerative Colitis
Castro-Dopico, T., Dennison, T. W., Ferdinand, J. R., Mathews, R. J., Fleming, A., Clift, D., Stewart, B. J., Jing, C., Strongili, K., Labzin, L. I., et al. (2019) · Immunity · doi:10.1016/j.immuni.2019.02.006 · Cited by 248
Blockade of IL-23: What is in the Pipeline?
Parigi, T. L., Iacucci, M., & Ghosh, S. (2022) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjab185 · Cited by 93
Self-citationInflammatory Bowel Disease: Emerging Therapies and Future Treatment Strategies
Bretto, E., Ribaldone, D. G., Caviglia, G. P., Saracco, G. M., Bugianesi, E., & Frara, S. (2023) · Biomedicines · doi:10.3390/biomedicines11082249 · Cited by 58
Induction of a colitogenic phenotype in Th1-like cells depends on interleukin-23 receptor signaling
Pawlak, M., DeTomaso, D., Schnell, A., Meyer zu Horste, G., Lee, Y., Nyman, J., Dionne, D., Regan, B. M. L., Singh, V., Delorey, T., et al. (2022) · Immunity · doi:10.1016/j.immuni.2022.08.007 · Cited by 49
Magro, F., Moreira, P. L., Catalano, G., Alves, C., Roseira, J., Estevinho, M. M., Silva, I., Dignass, A., Peyrin‐Biroulet, L., Danese, S., et al. (2023) · United European Gastroenterology Journal · doi:10.1002/ueg2.12366 · Cited by 30
Jain, A., Marrie, R. A., Shafer, L. A., Graff, L. A., Patten, S. B., El-Gabalawy, R., Sareen, J., Bolton, J. M., Fisk, J. D., & Bernstein, C. N. (2020) · Crohn's & Colitis 360 · doi:10.1093/crocol/otz053 · Cited by 16
Metadata
- Authors
- Sandborn, W. J., Gasink, C., Gao, L.-L., Blank, M. A., Johanns, J., Guzzo, C., Sands, B. E., Hanauer, S. B., Targan, S., Rutgeerts, P., Ghosh, S., de Villiers, W. J. S., Panaccione, R., Greenberg, G., Schreiber, S., Lichtiger, S., & Feagan, B. G.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2012-10-18
- Volume
- 367
- Issue
- 16
- Pages
- 1519-1528
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2085127303
- Cited by
- 1,134
- References
- 24
- FWCI
- 45.17
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.